Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
- PMID: 26109489
- PMCID: PMC4843946
- DOI: 10.1002/art.39169
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
Erratum in
-
Amended 95% confidence intervals in tables in the article by Jani et al (Arthritis Rheumatol, August 2015).Arthritis Rheumatol. 2015 Nov;67(11):3096. doi: 10.1002/art.39461. Arthritis Rheumatol. 2015. PMID: 26508467 Free PMC article. No abstract available.
Abstract
Objective: To investigate whether antidrug antibodies and/or drug non-trough levels predict the long-term treatment response in a large cohort of patients with rheumatoid arthritis (RA) treated with adalimumab or etanercept and to identify factors influencing antidrug antibody and drug levels to optimize future treatment decisions.
Methods: A total of 331 patients from an observational prospective cohort were selected (160 patients treated with adalimumab and 171 treated with etanercept). Antidrug antibody levels were measured by radioimmunoassay, and drug levels were measured by enzyme-linked immunosorbent assay in 835 serial serum samples obtained 3, 6, and 12 months after initiation of therapy. The association between antidrug antibodies and drug non-trough levels and the treatment response (change in the Disease Activity Score in 28 joints) was evaluated.
Results: Among patients who completed 12 months of followup, antidrug antibodies were detected in 24.8% of those receiving adalimumab (31 of 125) and in none of those receiving etanercept. At 3 months, antidrug antibody formation and low adalimumab levels were significant predictors of no response according to the European League Against Rheumatism (EULAR) criteria at 12 months (area under the receiver operating characteristic curve 0.71 [95% confidence interval (95% CI) 0.57, 0.85]). Antidrug antibody-positive patients received lower median dosages of methotrexate compared with antidrug antibody-negative patients (15 mg/week versus 20 mg/week; P = 0.01) and had a longer disease duration (14.0 versus 7.7 years; P = 0.03). The adalimumab level was the best predictor of change in the DAS28 at 12 months, after adjustment for confounders (regression coefficient 0.060 [95% CI 0.015, 0.10], P = 0.009). Etanercept levels were associated with the EULAR response at 12 months (regression coefficient 0.088 [95% CI 0.019, 0.16], P = 0.012); however, this difference was not significant after adjustment. A body mass index of ≥30 kg/m(2) and poor adherence were associated with lower drug levels.
Conclusion: Pharmacologic testing in anti-tumor necrosis factor-treated patients is clinically useful even in the absence of trough levels. At 3 months, antidrug antibodies and low adalimumab levels are significant predictors of no response according to the EULAR criteria at 12 months.
© 2015 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.
Similar articles
-
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.JAMA Netw Open. 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098. JAMA Netw Open. 2023. PMID: 37436748 Free PMC article.
-
Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.Ann Rheum Dis. 2015 Mar;74(3):e16. doi: 10.1136/annrheumdis-2013-203893. Epub 2014 Jan 17. Ann Rheum Dis. 2015. PMID: 24442879
-
Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.Arthritis Rheum. 2012 Dec;64(12):3850-5. doi: 10.1002/art.34680. Arthritis Rheum. 2012. PMID: 22933315
-
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2019 May 24;5:CD010455. doi: 10.1002/14651858.CD010455.pub3. PMID: 25264908 Updated. Review.
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420. Health Technol Assess. 2006. PMID: 17049139 Review.
Cited by
-
Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients.Front Immunol. 2018 Dec 5;9:2865. doi: 10.3389/fimmu.2018.02865. eCollection 2018. Front Immunol. 2018. PMID: 30568660 Free PMC article.
-
Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review.Pharmaceutics. 2023 Feb 25;15(3):766. doi: 10.3390/pharmaceutics15030766. Pharmaceutics. 2023. PMID: 36986627 Free PMC article. Review.
-
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.JAMA Netw Open. 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098. JAMA Netw Open. 2023. PMID: 37436748 Free PMC article.
-
Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis.Pharmaceutics. 2024 May 23;16(6):702. doi: 10.3390/pharmaceutics16060702. Pharmaceutics. 2024. PMID: 38931826 Free PMC article.
-
The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis.Ther Adv Musculoskelet Dis. 2020 Feb 7;12:1759720X20904850. doi: 10.1177/1759720X20904850. eCollection 2020. Ther Adv Musculoskelet Dis. 2020. PMID: 32095163 Free PMC article. Review.
References
-
- Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9. - PubMed
-
- Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45. - PubMed
-
- Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739–45. - PubMed
-
- Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long‐term follow‐up. JAMA 2011;305:1460–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G1001518/MRC_/Medical Research Council/United Kingdom
- 20385/ARC_/Arthritis Research UK/United Kingdom
- 20088/VAC_/Versus Arthritis/United Kingdom
- G1000417/MRC_/Medical Research Council/United Kingdom
- 20088/ARC_/Arthritis Research UK/United Kingdom
- 19791/VAC_/Versus Arthritis/United Kingdom
- G1000417/94909/MRC_/Medical Research Council/United Kingdom
- 19791/ARC_/Arthritis Research UK/United Kingdom
- MR/L01629X/1/MRC_/Medical Research Council/United Kingdom
- G1001516/MRC_/Medical Research Council/United Kingdom
- MR/K015346/1/MRC_/Medical Research Council/United Kingdom
- 20380/ARC_/Arthritis Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical